Revenue for Q1 FY23 has increased by 9% YoY to ₹ 6,235.9 crores. Profits have fallen by 32% YoY to ₹ 520.5
Categories
Health Care
Divi’s Laboratories Ltd (DIVISLAB) Q1 FY23 Earnings Concall Transcript
Divi's Laboratories Ltd (NSE:DIVISLAB) Q1 FY23 Earnings Concall dated Aug. 12, 2022 Corporate Participants: Satish Choudhury -- Company Secretary and Chief Investor
Infographic: Divi’s Lab Q1 results out, Net profit rises 26%
On Friday, Pharmaceuticals company Divis Laboratories reported a 26% rise in its consolidated net profit at ₹702 crore as compared to ₹557
Hikal Limited (HIKAL) Q2 FY23 Earnings Concall Transcript
Hikal Limited (NSE:HIKAL) Q2 FY23 Earnings Concall dated Aug. 11, 2022 Corporate Participants: Sameer Hiremath -- Managing Director Manoj Mehrotra -- President-Pharmaceuticals Vimal
Zydus Lifesciences Ltd Q1FY23; Profit suffer with rise in expenses
Revenue for Q1 FY23 has increased by 1.8% YoY to ₹40,727 millions. Profits decreased by 12% YoY to ₹5,183 millions because Total
Glenmark Life Sciences Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/02Igs_HUAfo Key highlights from Glenmark Life Sciences Limited (GLS) Q1 FY23 Earnings Concall Q&A Highlights: [00:14:56] Neha Manpuria from Bank of America
Rainbow Children’s Medicare Ltd (RAINBOW) Q2 FY23 Earnings Concall Transcript
Rainbow Children's Medicare Ltd (NSE:RAINBOW) Q2 FY23 Earnings Concall dated Aug. 09, 2022 Corporate Participants: Siddharth Rangnekar -- Investor Relations Ramesh Kancharla
SUVEN PHARMACEUTICALS LTD (SUVEN) Q1 FY23 Earnings Concall Transcript
SUVEN PHARMACEUTICALS LTD (NSE: SUVEN) Q1 FY23 Earnings Concall dated Aug. 08, 2022 Corporate Participants: Rishab Barar -- Investor Relations Venkat Jasti -- Managing Director Analysts:
Earnings Infographic: Dr. Lal PathLabs Q1 2023 revenue and profit decline
Dr. Lal PathLabs Ltd (NSE: LALPATHLAB), a leading provider of diagnostic and related healthcare services, has reported lower revenues and earnings for
Dr Lal PathLabs Ltd Q1 FY23 Earnings Conference Call Insights
https://youtu.be/GyHJJGLWdjg Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q1 FY23 Earnings Concall Management Update: LALPATHLAB said it clocked the highest quarterly
Torrent Pharmaceuticals Ltd Q1 FY23 Earnings Conference Call Insights
Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q1 FY23 Earnings Concall Management Update: TORNTPHARM launched four products in 1Q23 and will be
Sun Pharmaceutical Industries Ltd Q1 FY23 Earnings Conference Call Insights
Key highlights from Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY23 Earnings Concall Management Update: SUNPHARMA recorded the highest ever quarterly revenue in
Piramal Enterprises Limited Q1FY23; 8% fall in Profits
Revenue for Q1 FY23 has increased by 22% YoY to ₹ 3,548 crores. Profits have fallen by 8% YoY to ₹ 496.09
Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY23 Earnings Concall Transcript
Sun Pharmaceutical Industries Ltd (NSE:SUNPHARMA) Q1 FY23 Earnings Concall dated Jul. 29, 2022 Corporate Participants: Nimish Desai -- Investor Relations Dilip Shanghvi
Laurus Labs Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/gMXrmnAGz9Y Key highlights from Laurus Labs Limited (LAURUSLABS) Q1 FY23 Earnings Concall Management Update: LAURUSLABS said it expects the US filing pace
Torrent Pharmaceuticals Ltd (TORNTPHARM) Q1 FY22 Earnings Concall Transcript
Torrent Pharmaceuticals Ltd (NSE:TORNTPHARM) Q1 FY22 Earnings Concall dated Jul. 29, 2022 Corporate Participants: Sudhir Menon -- Executive Director, Finance and Chief
Cipla Limited (CIPLA) Q1 FY23 Earnings Concall Transcript
Cipla Limited (NSE:CIPLA) Q1 FY23 Earnings Concall dated Jul. 29, 2022 Corporate Participants: Naveen Bansal -- Head of Investor Relations Umang Vohra
Dr Reddy’s Laboratories Ltd. Q1FY23; 6% growth in Revenue
Revenue for Q1 FY23 has increased by 6% YoY to ₹ 52,154 millions. Profits have grown by 108% YoY to ₹ 11,876
SBI LIFE INSURANCE CO LTD (SBILIFE) Q1 FY23 Earnings Concall Transcript
SBI LIFE INSURANCE CO LTD (NSE:SBILIFE) Q1 FY23 Earnings Concall dated Jul. 28, 2022 Corporate Participants: Mahesh Kumar Sharma -- Managing Director and
Dr Lal PathLabs Ltd (LALPATHLAB) Q1 FY23 Earnings Concall Transcript
Dr Lal PathLabs Ltd (NSE:LALPATHLAB) Q1 FY23 Earnings Concall dated Jul. 28, 2022 Corporate Participants: Arvind Lal -- Executive Chairman Om Prakash
Biocon Limited (BIOCON) Q1 FY23 Earnings Concall Transcript
Biocon Limited (NSE : BIOCON) Q1 FY23 Earnings Concall dated July. 27, 2022 Corporate Participants: Kiran Mazumdar Shaw -- Executive Chairperson Biocon Limited and